(1 reference)-
- Target Alle Mu Opioid Receptor 1 (OPRM1) Produkte
- Mu Opioid Receptor 1 (OPRM1) (Opioid Receptor, mu 1 (OPRM1))
- Protein Region
- AA 384-398
- Applikation
- Blocking Peptide (BP), Control Peptide (CP)
- Verwendungszweck
- MOR (Opioid Receptor-Mu) Peptide Control
- Produktmerkmale
- The peptide control for Mu Opioid Receptor is intended for the immunoadsorption of Mu Opioid Receptor antiserum, ABIN617908. Preadsorption of Mu Opioid Receptor antiserum, diluted according to the antibody specification sheet, with 10µg/ml Mu Opioid Receptor peptide immunogen following the instructions below provides complete blockage of Mu Opioid Receptor immunolabeling. The peptide is provided as lyophilized rat Mu Opioid Receptor, sequence (384-398). Also, this antiserum contains ≤ 0.09% sodium azide.
- Aufreinigung
- Purified
-
-
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Reconstitute vial with 500 µl of PBS/Triton X-100 (0.05M sodium phosphate, 0.15M sodium chloride, 0.3% Triton X-100, pH 7.4), put the stopper back on and vortex lightly until dissolved.
- Konservierungsmittel
- Sodium azide
- Informationen zur Lagerung
-
Prior to reconstitution, as described below, store at -15°C or lower.
After reconstitution, use immediately or refrigerate at 2°- 8°C. For long-term storage, aliquot and freeze at -15°C or lower. Avoid repeated freeze/thaw cycles.
-
-
: "Dynamic temporal and spatial regulation of mu opioid receptor expression in primary afferent neurons following spinal nerve injury." in: European journal of pain (London, England), Vol. 15, Issue 7, pp. 669-75, (2011) (PubMed).
-
: "Dynamic temporal and spatial regulation of mu opioid receptor expression in primary afferent neurons following spinal nerve injury." in: European journal of pain (London, England), Vol. 15, Issue 7, pp. 669-75, (2011) (PubMed).
-
- Target
- Mu Opioid Receptor 1 (OPRM1) (Opioid Receptor, mu 1 (OPRM1))
-
Sie sind hier:
